Elaine Elisabetsky, PhD, to Discuss Plant-Based Schizophrenia Treatments

Jaguar Health, Inc. announced that Dr. Elaine Elisabetsky will speak about her research on plant-based medicines for schizophrenia on August 2, 2024. Her presentation is part of the Norman R. Farnsworth Lecture series at the University of Illinois Chicago College of Pharmacy.

A member of Jaguar's Entheogen Therapeutics Initiative, Dr. Elisabetsky is also an advisor to Magdalena Biosciences, formed by Jaguar and Filament Health. Recently, Jaguar licensed a botanical drug candidate for schizophrenia to Magdalena Biosciences. This candidate, derived from a medicinal plant, shows antipsychotic activity and could be the first in a new class of plant-based antipsychotic compounds.

The global schizophrenia treatment market, valued at $8.29 billion in 2024, is projected to grow to $13.41 billion by 2032. Schizophrenia affects approximately 1% of the U.S. population, and up to 34% of patients do not respond to existing treatments.

Dr. Elisabetsky's research spans psychoneuropharmacology and ethnopharmacology, with extensive fieldwork in the Brazilian Amazon. She has contributed significantly to the development of plant-based medicines and has published extensively in scientific journals.